Raymond Y. Wang
Elite in Pompe Disease

Dr. Raymond Y. Wang

Pediatrics | Medical Genetics
CHOC Clinic
1201 W La Veta Ave, 
Orange, CA 
Elite in Pompe Disease
CHOC Clinic
1201 W La Veta Ave, 
Orange, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raymond Wang is a Pediatrics specialist and a Medical Genetics provider in Orange, California. Dr. Wang and is rated as an Elite provider by MediFind in the treatment of Pompe Disease. His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Pompe Disease.

His clinical research consists of co-authoring 90 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Pompe Disease.

Residency
Cedars-Sinai Medical Center, Los Angeles, CA
Specialties
Pediatrics
Medical Genetics
Licenses
Pediatrics in CA
Hospital Affiliations
Children's Hospital Of Orange County
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CHOC Clinic
1201 W La Veta Ave, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Cerliponase Alfa Observational Study
Cerliponase Alfa Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: May 25, 2025
Intervention Type: Drug, Device
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency (Neuronal Ceroid Lipofuscinosis Type 2) Patients
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency (Neuronal Ceroid Lipofuscinosis Type 2) Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2024
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Intracisternal RGX-111 in Subjects With Mucopolysaccharidosis Type I
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Intracisternal RGX-111 in Subjects With Mucopolysaccharidosis Type I
Enrollment Status: Active_not_recruiting
Publish Date: December 06, 2023
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human β-Galactosidase cDNA for Treatment of GM1 Gangliosidosis
An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human β-Galactosidase cDNA for Treatment of GM1 Gangliosidosis
Enrollment Status: Terminated
Publish Date: June 09, 2023
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drug: AGT-181
Study Phase: Phase 1
A Prospective, Observational Study of Pediatric Patients With Neuronopathic Forms of MPS II (Hunter Syndrome)
A Prospective, Observational Study of Pediatric Patients With Neuronopathic Forms of MPS II (Hunter Syndrome)
Enrollment Status: Withdrawn
Publish Date: October 10, 2022
Intervention Type: Other
Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA
Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA
Enrollment Status: Unknown
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Enrollment Status: Completed
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

90 Total Publications

Human iPSC-derived neural stem cells engraft and improve pathophysiology of MPS I mice.
Human iPSC-derived neural stem cells engraft and improve pathophysiology of MPS I mice.
Journal: Molecular therapy. Methods & clinical development
Published: August 23, 2024
Similar Doctors
Elite in Pompe Disease
Dr. Virginia E. Kimonis
Medical Genetics | Pediatrics
Elite in Pompe Disease
Dr. Virginia E. Kimonis
Medical Genetics | Pediatrics

Uc Regents Uci Dept Of Pediatrics

101 The City Dr S, 
Orange, CA 
 (1.5 mi)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Virginia Kimonis is a Medical Genetics specialist and a Pediatrics provider in Orange, California. Dr. Kimonis and is rated as an Elite provider by MediFind in the treatment of Pompe Disease. Her top areas of expertise are Prader-Willi Syndrome, Pompe Disease, Fabry Disease, Danon Disease, and Hormone Replacement Therapy (HRT).

Advanced in Pompe Disease
Dr. Nicola Longo
Medical Genetics | Pediatrics
Advanced in Pompe Disease
Dr. Nicola Longo
Medical Genetics | Pediatrics

Uc Regents

10833 Leconte Ave, 
Los Angeles, CA 
 (38.4 mi)
310-825-9124
Experience:
43+ years
Languages Spoken:
English, Hindi, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicola Longo is a Medical Genetics specialist and a Pediatrics provider in Los Angeles, California. Dr. Longo has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Pompe Disease. His top areas of expertise are Megalencephalic Leukoencephalopathy with Subcortical Cysts, Multiple Sulfatase Deficiency, Gaucher Disease Type 3, and Gaucher Disease Type 2. Dr. Longo is currently accepting new patients.

Experienced in Pompe Disease
Dr. Angela Myers
Medical Genetics | Pediatrics
Experienced in Pompe Disease
Dr. Angela Myers
Medical Genetics | Pediatrics

Uc Regents Uci Dept Of Pediatrics

101 The City Dr S, 
Orange, CA 
 (1.5 mi)
714-456-7004
Languages Spoken:
English
See accepted insurances

Angela Myers is a Medical Genetics specialist and a Pediatrics provider in Orange, California. Dr. Myers and is rated as an Experienced provider by MediFind in the treatment of Pompe Disease. Her top areas of expertise are Maternal Hyperphenylalaninemia, Dihydropteridine Reductase Deficiency, Phenylketonuria (PKU), and Ehlers-Danlos Syndrome (EDS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wang's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 13 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile